Rep. Marjorie Taylor Greene Purchases Shares of Amgen Inc. (NASDAQ:AMGN)

Representative Marjorie Taylor Greene (R-Georgia) recently bought shares of Amgen Inc. NASDAQ: AMGN. In a filing disclosed on May 06th, the Representative disclosed that they had bought between $1,001 and $15,000 in Amgen stock on May 5th. The trade occurred in the Representative's "MARJORIE IRA" account.

Representative Marjorie Taylor Greene also recently made the following trade(s):

• Purchased $1,001 - $15,000 in shares of AbbVie NYSE: ABBV on 5/5/2025.
• Purchased $1,001 - $15,000 in shares of Occidental Petroleum NYSE: OXY on 5/5/2025.
• Purchased $1,001 - $15,000 in shares of Paychex NASDAQ: PAYX on 5/5/2025.
• Purchased $1,001 - $15,000 in shares of MercadoLibre NASDAQ: MELI on 5/5/2025.
• Purchased $1,001 - $15,000 in shares of Starbucks NASDAQ: SBUX on 5/5/2025.
• Purchased $1,001 - $15,000 in shares of BP NYSE: BP on 5/5/2025.
• Purchased $1,001 - $15,000 in shares of Gilead Sciences NASDAQ: GILD on 5/5/2025.
• Purchased $1,001 - $15,000 in shares of BHP Group NYSE: BHP on 5/5/2025.
• Purchased $1,001 - $15,000 in shares of Advanced Micro Devices NASDAQ: AMD on 5/5/2025.
• Purchased $1,001 - $15,000 in shares of Alphabet NASDAQ: GOOG on 5/5/2025.

Amgen Stock Performance

NASDAQ AMGN opened at $275.84 on Thursday. The firm has a 50-day moving average price of $297.78 and a two-hundred day moving average price of $290.54. Amgen Inc. has a 12-month low of $253.30 and a 12-month high of $346.85. The company has a market capitalization of $148.31 billion, a P/E ratio of 36.54, a P/E/G ratio of 2.63 and a beta of 0.51. The company has a quick ratio of 0.95, a current ratio of 1.26 and a debt-to-equity ratio of 9.62.

Amgen (NASDAQ:AMGN - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The medical research company reported $4.90 EPS for the quarter, beating analysts' consensus estimates of $4.18 by $0.72. Amgen had a return on equity of 176.32% and a net margin of 12.24%. The business had revenue of $8.15 billion during the quarter, compared to the consensus estimate of $8.05 billion. During the same quarter in the previous year, the firm earned $3.96 earnings per share. Amgen's revenue for the quarter was up 9.4% compared to the same quarter last year. Analysts anticipate that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Friday, May 16th will be given a dividend of $2.38 per share. This represents a $9.52 dividend on an annualized basis and a yield of 3.45%. The ex-dividend date of this dividend is Friday, May 16th. Amgen's dividend payout ratio is 86.86%.

Insider Activity

In other news, EVP David M. Reese sold 25,225 shares of the company's stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $304.44, for a total transaction of $7,679,499.00. Following the transaction, the executive vice president now owns 36,922 shares in the company, valued at approximately $11,240,533.68. This represents a 40.59 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Murdo Gordon sold 8,771 shares of the stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $294.79, for a total transaction of $2,585,603.09. Following the transaction, the executive vice president now directly owns 44,186 shares in the company, valued at $13,025,590.94. This trade represents a 16.56 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 67,752 shares of company stock worth $20,160,532 in the last quarter. 0.69% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Amgen

Large investors have recently modified their holdings of the company. Centricity Wealth Management LLC acquired a new position in shares of Amgen in the 4th quarter valued at about $25,000. Pinney & Scofield Inc. acquired a new position in Amgen in the fourth quarter valued at approximately $26,000. First Pacific Financial boosted its holdings in shares of Amgen by 304.5% during the 1st quarter. First Pacific Financial now owns 89 shares of the medical research company's stock worth $28,000 after buying an additional 67 shares in the last quarter. Ritter Daniher Financial Advisory LLC DE grew its position in shares of Amgen by 66.2% during the 4th quarter. Ritter Daniher Financial Advisory LLC DE now owns 128 shares of the medical research company's stock worth $33,000 after buying an additional 51 shares during the period. Finally, Synergy Investment Management LLC bought a new stake in shares of Amgen in the 4th quarter valued at $34,000. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on AMGN shares. Cantor Fitzgerald began coverage on Amgen in a research report on Tuesday, April 22nd. They issued a "neutral" rating and a $305.00 target price on the stock. Bank of America lifted their price target on shares of Amgen from $275.00 to $294.00 and gave the company an "underperform" rating in a report on Wednesday, March 5th. UBS Group reissued a "neutral" rating and issued a $315.00 price objective (down previously from $319.00) on shares of Amgen in a research note on Friday, May 2nd. Truist Financial decreased their target price on shares of Amgen from $333.00 to $298.00 and set a "hold" rating on the stock in a research note on Wednesday, January 8th. Finally, Wells Fargo & Company reiterated an "equal weight" rating on shares of Amgen in a research note on Wednesday, February 5th. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating, nine have given a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus target price of $310.23.

About Representative Greene

Marjorie Taylor Greene (Republican Party) is a member of the U.S. House, representing Georgia's 14th Congressional District. She assumed office on January 3, 2021. Her current term ends on January 3, 2027. Greene (Republican Party) is running for re-election to the U.S. House to represent Georgia's 14th Congressional District. She declared candidacy for the 2026 election.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.